Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.73 |
| ▸ | CDK2 | P24941 | 20/20 | 0.73 |
| ▸ | CCND1 | P24385 | 15/20 | 0.73 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.73 |
| ▸ | CDK9 | P50750 | 5/20 | 0.73 |
| ▸ | CDK4 | P11802 | 4/20 | 0.73 |
| ▸ | CCND3 | P30281 | 1/20 | 0.72 |
| ▸ | RB1 | P06400 | 1/20 | 0.66 |
| ▸ | CDK1 | P06493 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22860530 | 1.00 | CCNE1 (0.73) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL22164779 | 0.98 | CCNE1 (0.76) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL29507753 | 0.98 | CCNE1 (0.76) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL22860414 | 0.97 | CCNE1 (0.75) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL29507883 | 0.97 | CCNE1 (0.75) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL22860395 | 0.93 | CCNE1 (0.66) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL29507716 | 0.93 | CCNE1 (0.66) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL22860648 | 0.91 | CCNE1 (0.68) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL29507786 | 0.91 | CCNE1 (0.68) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL22860262 | 0.90 | CCNE1 (0.64) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-09-01 | — | — | US | disclosed |
| EP-3993802-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CCNE1 40/4885CDK2 6/4885CCND1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.